A comparison of the activity of tigecycline against multiresistant clinical isolates of Staphylococcus aureus and Streptococcus agalactiae

Diagnostic Microbiology and Infectious Disease

Volumn 58, Issue 4, 2007, Pages 487-489

  Sorlozano, Antonio ^a   Gutierrez, Jose ^a   Roman, Eva ^b   de Dios Luna, Juan ^a   Roman, Juan ^b   Liebana, Jose ^b   Piedrola, Gonzalo ^a  

^a UNIVERSITY OF GRANADA   (Spain)

^b HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

Author keywords

Multiresistant; Staphylococcus aureus; Streptococcus agalactiae; Tigecycline

Indexed keywords

AMPICILLIN; BETA LACTAM ANTIBIOTIC; CEFOTAXIME; CLINDAMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; GENTAMICIN; GLYCOPEPTIDE; JOSAMYCIN; KANAMYCIN; LEVOFLOXACIN; LINEZOLID; OXACILLIN; PENICILLIN G; TEICOPLANIN; TELITHROMYCIN; TIGECYCLINE; TOBRAMYCIN; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; DILUTION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS AGALACTIAE;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS AGALACTIAE;

EID: 34547560082     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2007.02.009     Document Type: Article

References (16)

1. Betriu C., Culebras E., Gomez M., Rodriguez-Avial I., Sanchez B.A., Agreda M.C., and Picazo J.J. Erythromycin and clindamycin resistance and telithromycin susceptibility in Streptococcus agalactiae. Antimicrob. Agents Chemother. 47 (2003) 1112-1114
2. Betriu C., Rodriguez-Avial I., Gomez M., Culebras E., Lopez F., Alvarez J., Picazo J.J., and the Spanish Tigecycline Group. Antimicrobial activity of tigecycline against clinical isolates from Spanish medical centers. Second multicenter study. Diagn. Microbiol. Infect. Dis. 56 (2006) 437-444
3. Bradford P.A., Weaver-Sands D.T., and Petersen P.J. In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections. Clin. Infect. Dis. 41 (2005) 315-332
4. Canton R., Perez-Vazquez M., Oliver A., Sanchez Del Saz B., Gutierrez M.O., Martinez-Ferrer M., and Baquero F. Evaluation of the Wider system, a new computer-assisted image-processing device for bacterial identification and susceptibility testing. J. Clin. Microbiol. 38 (2000) 1339-1346
5. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved Standard. CLSI Publication M7-A7. 7th ed. (2006), Clinical and Laboratory Standards Institute, Wayne (PA)
6. Chopra I., Hawkey P.M., and Hinton M. Tetracyclines, molecular and clinical aspects. J. Antimicrob. Chemother. 29 (1992) 245-277
7. Fritsche T.R., Sader H.S., Stilwell M.G., Dowzicky M.J., and Jones R.N. Potency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections (2000-2004). Diagn. Microbiol. Infect. Dis. 52 (2005) 195-201
8. Gales A.C., and Jones R.N. Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates. Diagn. Microbiol. Infect. Dis. 36 (2000) 19-36
9. Gobernado M. Bacterial resistance and a new antibiotic: tigecycline. Rev. Esp. Quimioter. 19 (2006) 209-219
10. Hoban D.J., Bouchillon S.K., Johnson B.M., Johnson J.L., and Dowzicky M.J. In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004). Diagn. Microbiol. Infect. Dis. 52 (2005) 215-227
11. Milatovic D., Schmitz F.J., Verhoef J., and Fluit A.C. Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates. Antimicrob. Agents Chemother. 47 (2003) 400-404
12. Noskin G.A. Tigecycline: a new glycylcycline for treatment of serious infections. Clin. Infect. Dis. 41 (2005) 303-314
13. Sader H.S., Jones R.N., Dowzicky M.J., and Fritsche T.R. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit. Diagn. Microbiol. Infect. Dis. 52 (2005) 203-208
14. Sorlozano A., Gutierrez J., Salmeron A., Luna J.D., Martinez-Checa F., Roman J., and Piedrola G. Activity of tigecycline against clinical isolates of Staphylococcus aureus and extended-spectrum β-lactamase-producing Escherichia coli in Granada, Spain. Int. J. Antimicrob. Agents 28 (2006) 532-536
15. The Spanish Society of Obstetrics and Gynecology, The Spanish Society of Neonatology, The Spanish Society of Infectious Diseases and Clinical Microbiology, The Spanish Society of Chemotherapy, and The Spanish Society of Family and Community Medicine. Prevention of perinatal group B streptococcal disease. Spanish revised guidelines. Enferm. Infecc. Microbiol. Clin. 21 (2003) 417-423
16. Zinner S.H. Overview of antibiotic use and resistance: setting the stage for tigecycline. Clin. Infect. Dis. 41 (2005) 289-292